Impact Partnership Wealth LLC Makes New $70,000 Investment in Verve Therapeutics, Inc. (NASDAQ:VERV)

Impact Partnership Wealth LLC bought a new position in Verve Therapeutics, Inc. (NASDAQ:VERV) during the 4th quarter, Holdings Channel.com reports. The fund bought 12,466 shares of the company’s stock, valued at approximately $70,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp boosted its position in Verve Therapeutics by 27.0% in the third quarter. State Street Corp now owns 4,253,217 shares of the company’s stock worth $20,586,000 after purchasing an additional 903,809 shares during the last quarter. Novo Holdings A S lifted its position in shares of Verve Therapeutics by 20.0% during the 2nd quarter. Novo Holdings A S now owns 2,400,000 shares of the company’s stock valued at $11,712,000 after buying an additional 400,000 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Verve Therapeutics by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,600,687 shares of the company’s stock valued at $7,749,000 after buying an additional 40,915 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Verve Therapeutics by 72.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company’s stock valued at $7,547,000 after buying an additional 653,578 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Verve Therapeutics by 0.3% during the 3rd quarter. FMR LLC now owns 1,418,993 shares of the company’s stock valued at $6,868,000 after buying an additional 3,873 shares in the last quarter. 97.11% of the stock is owned by hedge funds and other institutional investors.

Verve Therapeutics Trading Down 1.0 %

Shares of VERV opened at $7.91 on Friday. The business’s 50 day moving average is $5.96 and its 200 day moving average is $5.82. The company has a market capitalization of $669.66 million, a PE ratio of -3.22 and a beta of 1.68. Verve Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last issued its earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.11. The company had revenue of $6.87 million for the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm’s quarterly revenue was up 120.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.72) EPS. Equities research analysts predict that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price objective on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. HC Wainwright lowered their price objective on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada lowered their price objective on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.